Short-selling firm Muddy Waters said in a legal brief that outside cyber security experts it hired have validated its claim that St. Jude Medical Inc. cardiac implants are vulnerable to potentially life-threatening cyber attacks.
The U.S. FDA placed a partial hold on Berkeley, Calif.-based Aduro Biotech’s LADD trials.
GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential $1 billion-a-year seller a step closer to market.
Former Democratic presidential candidate Bernie Sanders, in an opinion editorial published in the Los Angeles Times, urged Californians to approve a November ballot measure aimed at reining in pharmaceutical prices.
Two companies making vaccines to help the world eradicate polio are failing to produce enough, so many countries should prepare to give lower doses to make stocks last, a group of experts has advised the World Health Organization.
Heart attack survivors who participate in cardiac rehabilitation programs may survive longer, but feel no healthier, than they would without this follow-up care, a U.S. study suggests.
The World Medical Association (WMA), the top medical-ethics body, installed an Indian doctor facing corruption charges as its president despite controversy surrounding his appointment while legal cases are pending.
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
Merck & Co. ended a Phase III trial of Keytruda in advanced urothelial cancer because the immuno-oncology drug met its primary endpoint.